... San Antonio Breast Cancer Symposium 2023. Researchers found that Dato ... Some study authors declared affiliations with biotech, pharmaceutical, and/or ...
News
- Dato-DXd Deemed New Treatment Option for HR+, HER2- Advanced Breast Cancer
- Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast ...
... San Antonio Breast Cancer Symposium (SABCS). Information on the ... Intensity Therapeutics is a late-stage biotechnology company that applies novel ...
- Genentech's Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival ... - BioSpace
Full data are being presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium on Friday, December 8. Kadcyla is approved ...
- Intensity Therapeutics rockets on positive INT230-6 data - The Pharma Letter
... San Antonio Breast Cancer Symposium. The trial showed that: INT230-6 ... BiotechnologyBreast cancerConferencesDrug TrialINT230-6Intensity ...
- Neoadjuvant Treatment Combos Face Off in HER2+ Breast Cancer
These findings, from the APTneo trial (ClinicalTrials.gov Identifier: NCT03595592), were presented at the San Antonio Breast Cancer Symposium 2023.